Synairgen presents proof of concept study

RNS Number : 1429L

Synairgen plc

31 August 2012

 



Press release

Synairgen plc

('Synairgen' or the 'Company')

 Results of Synairgen's Phase II interferon beta proof of concept study to be presented at European Respiratory Society annual congress on 2 September

Southampton, UK - 31 August 2012: Synairgen plc (LSE: SNG) is pleased to announce that Professor Ratko Djukanovic, Chief Investigator on Synairgen's recent Phase II study of inhaled interferon beta, will present "The effects of interferon beta on cold-induced asthma exacerbations" during the session on emerging new treatments for asthma at the European Respiratory Society's 2012 Annual Congress. The presentation will take place at 12 noon on Sunday 2 September in Room C1 at the Reed Messe Wien Congress Center in Vienna.  

For further information, please contact:

Synairgen plc                                                                      Tel: + 44 (0) 23 8051 2800

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

FinnCap                                                                                Tel: + 44 (0) 20 7220 0500

Geoff Nash, Christopher Raggett (Corporate Finance)

Stephen Norcross, Simon Starr (Corporate Broking)

NewgateThreadneedle                                                     Tel: + 44 (0) 20 7653 9850

Graham Herring

Josh Royston

 

END

 

 

NRALLFVETEIIVIF